Loading company…
XUNGENE THERAPEUTICS develops RNA small molecule drugs for rare diseases and cancers.
XUNGENE THERAPEUTICS researches RNA small molecule drugs for rare diseases and cancers. It has technology platforms for RNA structure data, targeted drug screening, and AI analysis of RNA-small molecule interactions. Founded in 2023 and based in Beijing, China, it was co-founded by Prof. Qiangfeng Zhang and Prof. Yangming Wang. It received strategic investment from Tsinghua Holdings in 2023 and raised angel funding in September 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in